Oxygenta Pharmaceutical Limited

SSORGS

INE102E01018

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 28/06/2024 pm IST			5-day change	1st Jan Change
33.49 ^INR	-0.15%		-6.97%	+7.48%

21/05	Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding	CI
08/04	Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in funding	CI

Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding

May 21, 2024

On May 21, 2024, Oxygenta Pharmaceutical Limited closed the transaction. The company issued 17,00,000 shares to M V S Prasad Reddy, 2,00,000 shares to Amigos Molecular Solutions Private Limited and 1,00,000 to Rachamallu Aparna.

Latest news about Oxygenta Pharmaceutical Limited

Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding	21/05	CI
Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in funding	08/04	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance Officer	11/23/11	CI
Oxygenta Pharmaceutical Limited Announces Board Appointments	01/23/01	CI
Oxygenta Pharmaceutical Limited Approves Board Changes	04/23/04	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance Officer	01/23/01	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI
Sunil Vishram Chawda, Manoj Sunil Chawda, Aakanksha M. Chawda and Raghavender Rao Kanuganti made an offer to acquire a 26% stake in Oxygenta Pharmaceutical Limited for approximately INR 130 million.	27/23/27	CI
Oxygenta Pharmaceutical Limited announced a financing transaction	27/23/27	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	12/22/12	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Oxygenta Pharmaceutical Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
SS Organics Adopts New Name	11/22/11	MT
S.S. Organics Ltd. has Changed its Name to Oxygenta Pharmaceutical Limited	10/22/10	CI
S.S. Organics Limited Announces Resignation of Directors	07/21/07	CI
S.S. Organics Limited Announces Resignations of Directors	07/21/07	CI
S.S. Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	15/21/15	CI
S.S. Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	12/21/12	CI
S.S. Organics Limited announced that it has received INR 40 million in funding	12/21/12	CI
S.S. Organics Limited Announces Appointment of Company Secretary and Compliance Officer	01/21/01	CI
S.S. Organics Limited Announces Resignation of Vishal R from Company Secretary and Compliance Officer	01/21/01	CI

Chart Oxygenta Pharmaceutical Limited

Duration

Period

More charts

Company Profile

Oxygenta Pharmaceutical Limited is an India-based company, which is primarily engaged in the manufacturing of bulk drugs and active pharmaceutical ingredients (API). The Company is also engaged in the business of manufacturing all classes and kinds of drugs, including pharmaceutical preparation, and organic fine chemicals. Its APIâs products include pantoprazole sodium, vildagliptin, telmisartan, lacosamide, and sertraline hydrochloride. The Companyâs chemical products include 3-Amino-1-adamantanol, (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile, 2-N-Propyl-4-methyl-6-(1-methyl benzimidazole-2-yl) benzimidazole, Isobutyramide, 4-Aminobenzonitrile, and others. The Company has its manufacturing facilities situated at Sadasivapet Mandal, Sangareddy District, Telangana State.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OXYGENTA PHARMACEUTICAL LIMITED	+7.48%	14.26M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B